MA38974B2 - Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate - Google Patents
Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olateInfo
- Publication number
- MA38974B2 MA38974B2 MA38974A MA38974A MA38974B2 MA 38974 B2 MA38974 B2 MA 38974B2 MA 38974 A MA38974 A MA 38974A MA 38974 A MA38974 A MA 38974A MA 38974 B2 MA38974 B2 MA 38974B2
- Authority
- MA
- Morocco
- Prior art keywords
- dosage forms
- olate
- morpholin
- triazol
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des formes galéniques pharmaceutiques pour administration orale contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate (principe actif (i). Selon l'invention, le principe actif (i) est libéré. L'invention concerne également un procédé de production desdites formes galéniques, leur utilisation comme médicament, ainsi que leur utilisation pour la prophylaxie, la prophylaxie secondaire ou le traitement de maladies, en particulier les maladies cardiovasculaires, l'insuffisance cardiaque, l'anémie, les maladies rénales chroniques et l'insuffisance rénale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13189145 | 2013-10-17 | ||
PCT/EP2014/071855 WO2015055564A1 (fr) | 2013-10-17 | 2014-10-13 | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38974A1 MA38974A1 (fr) | 2017-05-31 |
MA38974B2 true MA38974B2 (fr) | 2020-11-30 |
Family
ID=49356354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38974A MA38974B2 (fr) | 2013-10-17 | 2014-10-13 | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate |
Country Status (35)
Country | Link |
---|---|
US (1) | US9827198B2 (fr) |
EP (1) | EP3057580B1 (fr) |
JP (1) | JP6525979B2 (fr) |
KR (1) | KR102330953B1 (fr) |
CN (1) | CN105636580B (fr) |
AP (1) | AP2016009135A0 (fr) |
AR (1) | AR098064A1 (fr) |
AU (1) | AU2014336389B2 (fr) |
BR (1) | BR112016007588A2 (fr) |
CA (1) | CA2927437C (fr) |
CL (1) | CL2016000857A1 (fr) |
CU (1) | CU24515B1 (fr) |
DK (1) | DK3057580T3 (fr) |
DO (1) | DOP2016000078A (fr) |
EA (1) | EA032932B1 (fr) |
ES (1) | ES2868228T3 (fr) |
GT (1) | GT201600072A (fr) |
HR (1) | HRP20210691T1 (fr) |
HU (1) | HUE054107T2 (fr) |
IL (1) | IL244933B (fr) |
JO (1) | JO3645B1 (fr) |
LT (1) | LT3057580T (fr) |
MA (1) | MA38974B2 (fr) |
MX (1) | MX2016004628A (fr) |
MY (1) | MY190202A (fr) |
NI (1) | NI201600054A (fr) |
PE (1) | PE20160669A1 (fr) |
PH (1) | PH12016500716B1 (fr) |
SA (1) | SA516370940B1 (fr) |
SI (1) | SI3057580T1 (fr) |
TN (1) | TN2016000135A1 (fr) |
TW (1) | TWI746418B (fr) |
UA (1) | UA119855C2 (fr) |
UY (1) | UY35784A (fr) |
WO (1) | WO2015055564A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020045607A1 (fr) * | 2018-08-31 | 2020-03-05 | アステラス製薬株式会社 | Composition pharmaceutique pour administration par voie orale |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
EP2133096A4 (fr) * | 2007-03-13 | 2011-11-16 | Dainippon Sumitomo Pharma Co | Comprimé à désintégration orale |
DE102010044131A1 (de) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
-
2014
- 2014-10-13 UA UAA201605150A patent/UA119855C2/uk unknown
- 2014-10-13 KR KR1020167009621A patent/KR102330953B1/ko active IP Right Grant
- 2014-10-13 SI SI201431801T patent/SI3057580T1/sl unknown
- 2014-10-13 PE PE2016000498A patent/PE20160669A1/es unknown
- 2014-10-13 BR BR112016007588A patent/BR112016007588A2/pt not_active Application Discontinuation
- 2014-10-13 JP JP2016523207A patent/JP6525979B2/ja active Active
- 2014-10-13 MX MX2016004628A patent/MX2016004628A/es unknown
- 2014-10-13 AU AU2014336389A patent/AU2014336389B2/en not_active Ceased
- 2014-10-13 DK DK14783642.3T patent/DK3057580T3/da active
- 2014-10-13 LT LTEP14783642.3T patent/LT3057580T/lt unknown
- 2014-10-13 CU CU2016000048A patent/CU24515B1/es unknown
- 2014-10-13 MY MYPI2016701355A patent/MY190202A/en unknown
- 2014-10-13 ES ES14783642T patent/ES2868228T3/es active Active
- 2014-10-13 HU HUE14783642A patent/HUE054107T2/hu unknown
- 2014-10-13 CN CN201480056547.1A patent/CN105636580B/zh active Active
- 2014-10-13 MA MA38974A patent/MA38974B2/fr unknown
- 2014-10-13 EP EP14783642.3A patent/EP3057580B1/fr active Active
- 2014-10-13 EA EA201690788A patent/EA032932B1/ru not_active IP Right Cessation
- 2014-10-13 US US15/029,215 patent/US9827198B2/en active Active
- 2014-10-13 AP AP2016009135A patent/AP2016009135A0/en unknown
- 2014-10-13 TN TN2016000135A patent/TN2016000135A1/en unknown
- 2014-10-13 WO PCT/EP2014/071855 patent/WO2015055564A1/fr active Application Filing
- 2014-10-13 CA CA2927437A patent/CA2927437C/fr active Active
- 2014-10-15 TW TW103135607A patent/TWI746418B/zh not_active IP Right Cessation
- 2014-10-15 UY UY0001035784A patent/UY35784A/es not_active Application Discontinuation
- 2014-10-16 JO JOP/2014/0295A patent/JO3645B1/ar active
- 2014-10-17 AR ARP140103868A patent/AR098064A1/es unknown
-
2016
- 2016-04-04 IL IL244933A patent/IL244933B/en active IP Right Grant
- 2016-04-08 DO DO2016000078A patent/DOP2016000078A/es unknown
- 2016-04-12 CL CL2016000857A patent/CL2016000857A1/es unknown
- 2016-04-14 SA SA516370940A patent/SA516370940B1/ar unknown
- 2016-04-14 NI NI201600054A patent/NI201600054A/es unknown
- 2016-04-14 GT GT201600072A patent/GT201600072A/es unknown
- 2016-04-15 PH PH12016500716A patent/PH12016500716B1/en unknown
-
2021
- 2021-05-04 HR HRP20210691TT patent/HRP20210691T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
MA37405A1 (fr) | Composés hétérocyclyle | |
MA34083B1 (fr) | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques | |
MA35576B1 (fr) | Nouveaux composés | |
MA35348B1 (fr) | 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk | |
MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
MA38398A1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
NZ628096A (en) | Cycloalkyloxy-n-substituted-benzenesulfonamide derivatives and uses thereof for treatment or prevention of pain | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
MA44948A1 (fr) | Inhibiteurs de bace 1 | |
EA201691061A1 (ru) | Лекарственные формы производных пирролидина для перорального введения | |
MA37742A1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA34671B1 (fr) | Sel de sodium de 1h-pyrazol-5-olate substitué | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
MA37455B1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
MA37721B1 (fr) | Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA38215A1 (fr) | Composition pharmaceutique ophtalmologique topique contenant regorafenib | |
MA38974B2 (fr) | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate | |
MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine |